SG11202012713RA - Method for producing a controlled mixture of two or more different antibodies - Google Patents
Method for producing a controlled mixture of two or more different antibodiesInfo
- Publication number
- SG11202012713RA SG11202012713RA SG11202012713RA SG11202012713RA SG11202012713RA SG 11202012713R A SG11202012713R A SG 11202012713RA SG 11202012713R A SG11202012713R A SG 11202012713RA SG 11202012713R A SG11202012713R A SG 11202012713RA SG 11202012713R A SG11202012713R A SG 11202012713RA
- Authority
- SG
- Singapore
- Prior art keywords
- producing
- different antibodies
- controlled mixture
- mixture
- controlled
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2893—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18179365 | 2018-06-22 | ||
| PCT/EP2019/066594 WO2019243626A1 (en) | 2018-06-22 | 2019-06-24 | Method for producing a controlled mixture of two or more different antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202012713RA true SG11202012713RA (en) | 2021-01-28 |
Family
ID=62841830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202012713RA SG11202012713RA (en) | 2018-06-22 | 2019-06-24 | Method for producing a controlled mixture of two or more different antibodies |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12247065B2 (https=) |
| EP (1) | EP3810649A1 (https=) |
| JP (2) | JP2021528435A (https=) |
| CN (1) | CN112513074A (https=) |
| CA (1) | CA3104390A1 (https=) |
| IL (1) | IL279528A (https=) |
| MA (1) | MA52945A (https=) |
| SG (1) | SG11202012713RA (https=) |
| WO (1) | WO2019243626A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI874341B (zh) | 2018-12-18 | 2025-03-01 | 美商健生生物科技公司 | 產生異二聚體抗體之方法 |
| JP7778705B2 (ja) | 2020-02-21 | 2025-12-02 | ジェンマブ ビー.ブイ. | 糖蛋白質の定量のための方法 |
| EP4372001A4 (en) * | 2021-07-14 | 2025-02-12 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | ANTIGEN-BINDING MOLECULE SPECIFICALLY BINDING TO HGFR AND EGFR, AND PHARMACEUTICAL USE THEREOF |
| EP4624493A1 (en) * | 2022-11-24 | 2025-10-01 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pharmaceutical composition comprising bispecific antibody specifically binding to hgfr and egfr |
| TW202509077A (zh) * | 2023-06-30 | 2025-03-01 | 丹麥商珍美寶股份有限公司 | 與纖維母細胞活化蛋白α及死亡受體4結合之抗體 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| DE59309332D1 (de) * | 1993-12-27 | 1999-03-04 | Rotkreuzstiftung Zentratrallab | Verfahren zur Herstellung eines Konzentrates von Anti-D-Immunoglobulin G und pharmazeutische Zusammensetzung, die dieses enthält |
| JP4593783B2 (ja) | 1998-07-21 | 2010-12-08 | ゲンマブ・アクティーゼルスカブ | 抗c型肝炎ウイルス抗体およびその使用 |
| CA2450285C (en) | 2001-06-13 | 2016-08-02 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (egfr) |
| DK2314629T4 (da) | 2002-07-18 | 2023-02-06 | Merus Nv | Rekombinant produktion af blandinger af antistoffer |
| BRPI0315295C1 (pt) | 2002-10-17 | 2021-05-25 | Genmab As | anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão |
| SI1583830T1 (sl) | 2003-01-07 | 2006-12-31 | Symphogen As | Postopek za pripravo rekombinantnih poliklonskih proteinov |
| US8288109B2 (en) * | 2004-07-20 | 2012-10-16 | Symphogen A/S | Procedure for structural characterization of a recombinant polyclonal protein or a polyclonal cell line |
| EA014182B1 (ru) * | 2004-07-20 | 2010-10-29 | Симфоген А/С | КОМПОЗИЦИЯ ПОЛИКЛОНАЛЬНЫХ АНТИ-RhD АНТИТЕЛ, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЕ КОМПОЗИЦИИ |
| EP2009101B1 (en) | 2006-03-31 | 2017-10-25 | Chugai Seiyaku Kabushiki Kaisha | Antibody modification method for purifying bispecific antibody |
| CL2007003622A1 (es) | 2006-12-13 | 2009-08-07 | Medarex Inc | Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales. |
| MX2009012526A (es) * | 2007-05-25 | 2009-12-09 | Symphogen As | Metodo para fabricar una proteina policlonal recombinante. |
| NZ588651A (en) | 2008-04-23 | 2012-04-27 | Symphogen As | Methods for manufacturing a polyclonal protein |
| WO2010089387A1 (en) | 2009-02-09 | 2010-08-12 | Morphosys Ag | Production of oligoclonal mixtures of immunoglobulins in single cells |
| MY192182A (en) | 2009-06-26 | 2022-08-04 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
| SG10201501803YA (en) | 2010-03-12 | 2015-05-28 | Immunogen Inc | Cd37-binding molecules and immunoconjugates thereof |
| HRP20241208T1 (hr) | 2010-04-20 | 2024-11-22 | Genmab A/S | Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju |
| CA2800769C (en) | 2010-05-27 | 2021-11-02 | Genmab A/S | Monoclonal antibodies against her2 epitope |
| WO2012068317A2 (en) | 2010-11-16 | 2012-05-24 | Excelimmune, Inc. | Methods for producing recombinant proteins |
| CN103796678B (zh) | 2011-04-20 | 2018-02-27 | 健玛保 | 针对her2的双特异性抗体 |
| UA117901C2 (uk) | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування |
| PT2768857T (pt) | 2011-10-19 | 2020-01-27 | Novimmune Sa | Métodos para purificar anticorpos |
| EP3517548A1 (en) * | 2012-03-13 | 2019-07-31 | NovImmune S.A. | Readily isolated bispecific antibodies with native immunoglobulin format |
| AU2013322710A1 (en) * | 2012-09-25 | 2015-04-16 | Glenmark Pharmaceuticals S.A. | Purification of hetero-dimeric immunoglobulins |
| KR20200024345A (ko) | 2013-01-10 | 2020-03-06 | 젠맵 비. 브이 | 인간 IgG1 Fc 영역 변이체 및 그의 용도 |
| HK1222871A1 (zh) | 2013-05-13 | 2017-07-14 | Medimmune, Llc | 具有最小单体分离的重组多克隆抗体多聚体的分离 |
| SMT202000265T1 (it) | 2014-07-11 | 2020-07-08 | Genmab As | Anticorpi che legano axl |
| EP3233907B1 (en) * | 2014-12-19 | 2021-03-03 | Genmab A/S | Rodent bispecific heterodimeric proteins |
| US12595316B2 (en) | 2015-07-09 | 2026-04-07 | Genmab A/S | Bispecific and multispecific antibodies and method for isolation of such |
| US11020686B2 (en) * | 2016-08-16 | 2021-06-01 | Regeneron Pharmaceuticals, Inc. | Methods for quantitating individual antibodies from a mixture |
-
2019
- 2019-06-24 EP EP19734332.0A patent/EP3810649A1/en active Pending
- 2019-06-24 JP JP2020571498A patent/JP2021528435A/ja active Pending
- 2019-06-24 CA CA3104390A patent/CA3104390A1/en active Pending
- 2019-06-24 SG SG11202012713RA patent/SG11202012713RA/en unknown
- 2019-06-24 CN CN201980050655.0A patent/CN112513074A/zh active Pending
- 2019-06-24 WO PCT/EP2019/066594 patent/WO2019243626A1/en not_active Ceased
- 2019-06-24 US US17/253,286 patent/US12247065B2/en active Active
- 2019-06-24 MA MA052945A patent/MA52945A/fr unknown
-
2020
- 2020-12-17 IL IL279528A patent/IL279528A/en unknown
-
2024
- 2024-05-28 JP JP2024086125A patent/JP2024109884A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL279528A (en) | 2021-01-31 |
| CA3104390A1 (en) | 2019-12-26 |
| JP2024109884A (ja) | 2024-08-14 |
| US12247065B2 (en) | 2025-03-11 |
| CN112513074A (zh) | 2021-03-16 |
| EP3810649A1 (en) | 2021-04-28 |
| WO2019243626A1 (en) | 2019-12-26 |
| JP2021528435A (ja) | 2021-10-21 |
| MA52945A (fr) | 2021-04-28 |
| US20210269509A1 (en) | 2021-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279528A (en) | A method for producing a controlled mixture of two or more different antibodies | |
| ES2949329T5 (en) | A method for producing a mixture of hydrocarbons | |
| SG11202103331WA (en) | Method for production of aviation fuel | |
| GB2573650B (en) | Method of forming glass-ceramic materials | |
| IL268470A (en) | A method for producing multispecific antibodies | |
| IL284026A (en) | Methods for producing heterodimeric antibodies | |
| IL265536A (en) | A method for the production of a crystalline form of the a modification of calcobuterol | |
| SG11202005684UA (en) | Method for producing carbonic ester | |
| GB201704115D0 (en) | Method of selecting for antibodies | |
| IL277227A (en) | A new form of ivermectin and a process for its preparation | |
| PL3733651T3 (pl) | Sposób wytwarzania kalkobutrolu | |
| IL287063A (en) | A method for producing a similar structure-biotissue | |
| SG11202103673UA (en) | Method for producing perfluorocycloalkene compound | |
| SG11202101704VA (en) | Method of producing piperylene | |
| GB201809783D0 (en) | A method of producing a structure | |
| HUP1800125A2 (en) | Process for production of iloprost | |
| HK40051514A (en) | Method for producing a controlled mixture of two or more different antibodies | |
| IL284086A (en) | Controlled Fucosylation of Antibodies | |
| IL279070A (en) | A method for the production of diarylpyridine derivatives | |
| SG11202107214UA (en) | Method for producing cyclobutane | |
| HUE070639T2 (hu) | Eljárás betonlapok elõállítására | |
| GB201914819D0 (en) | Method of selecting for antibodies | |
| GB201913333D0 (en) | Method of selecting for antibodies | |
| PT3231814T (pt) | Um método para produzir células b específicas de antigénio e a sua utilização para a produção de células de hibridoma e anticorpos monoclonais | |
| GB201903270D0 (en) | Method of selecting for antibodies |